<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669123</url>
  </required_header>
  <id_info>
    <org_study_id>CS/IV/PSO/ART</org_study_id>
    <nct_id>NCT00669123</nct_id>
  </id_info>
  <brief_title>Chondroitin Sulphate Efficay/Safety in Patients With Knee Osteoarthritis and Psoriasis</brief_title>
  <official_title>Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioiberica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioiberica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpouse of this study is to determine the efficacy and safety of chondroitin sulphate
      conventional treatment in patients with both knee osteoarthritis and plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Huskisson Visual Analogue Scale</measure>
    <time_frame>Monthly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index</measure>
    <time_frame>Monthly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lequesne Index</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue medication</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Health Questionaire</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Lession Severity Scale</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of improvement</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological assessment of skin biopsies</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Osteoarthritis</condition>
  <condition>Psoriasis</condition>
  <condition>Joint Diseases</condition>
  <condition>Muskuloskeletal Diseases</condition>
  <condition>Skin Diseases</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chondroitin sulphate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chondroitin sulphate</intervention_name>
    <description>Chondroitin sulphate 800 mg/day</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Condrosan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary knee OA according to ACR criteria;

          -  OA of radiological stages 1 to 3 according to Kellgren-Lawrence;

          -  VAS of pain ≥30;

          -  PASI ≥ 5.

        Exclusion Criteria:

          -  Known allergy to chondroitin sulphate;

          -  Other bone and articular diseases such as chondrocalcinosis, Paget's disease,
             rheumatoid arthritis, psoriatic arthritis, acromegaly, hemochromatosis, Wilson's
             disease;

          -  Patients with skin conditions that could interfere in the clinical trial evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pere Benito, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Montserrat Pérez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Poal de Reumatología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingrid Möller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Poal de Reumatología</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Poal de Reumatología</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>April 28, 2008</last_update_submitted>
  <last_update_submitted_qc>April 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Josep Vergés Milano, Scientific Medical Director</name_title>
    <organization>Bioiberica</organization>
  </responsible_party>
  <keyword>Chondroitin sulphate</keyword>
  <keyword>Knee osteoarthritis</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

